ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $226,193 | -31.6% | 20,250 | +31.1% | 0.00% | -100.0% |
Q2 2023 | $330,630 | -47.1% | 15,450 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $624,798 | -11.6% | 15,450 | +1.6% | 0.00% | -50.0% |
Q4 2022 | $707,104 | -61.3% | 15,200 | -56.9% | 0.00% | -60.0% |
Q3 2022 | $1,829,000 | +13.5% | 35,270 | +3.5% | 0.01% | +25.0% |
Q2 2022 | $1,611,000 | -40.6% | 34,084 | -10.5% | 0.00% | -33.3% |
Q1 2022 | $2,712,000 | -4.8% | 38,095 | 0.0% | 0.01% | +20.0% |
Q4 2021 | $2,849,000 | +140.0% | 38,095 | +82.3% | 0.01% | +150.0% |
Q3 2021 | $1,187,000 | +29.0% | 20,900 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $920,000 | -8.5% | 20,900 | +2.5% | 0.00% | 0.0% |
Q1 2021 | $1,006,000 | +41.5% | 20,400 | +20.7% | 0.00% | 0.0% |
Q4 2020 | $711,000 | -8.1% | 16,900 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $774,000 | -8.8% | 16,900 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $849,000 | -2.3% | 16,900 | 0.0% | 0.00% | -33.3% |
Q1 2020 | $869,000 | -5.6% | 16,900 | +13.4% | 0.00% | +50.0% |
Q4 2019 | $921,000 | – | 14,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |